Xenetic Biosciences is a biopharmaceutical company. Co.'s drug candidates pipeline include: XCART, which is a CAR T cell platform technology engineered to target patient-specific tumor neoantigens; ErepoXen (polysialylated erythropoietin), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients; XBIO-101, which is an internal candidate with orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy; and OncoHist, which utilizes the properties of modified human histone H1.3 for targeted cell killing. We show 36 historical shares outstanding datapoints in our coverage of XBIO's shares outstanding history.
Understanding the changing numbers of XBIO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XBIO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XBIO by allowing them to research XBIO shares outstanding history
as well as any other stock in our coverage universe. |
Free XBIO Email Alerts:
Video: Shares Outstanding Importance
